Generic Cymbalta Settlement: Up to $10 Per Prescription for Contamination
One of the more consequential pharmacy class action cases in recent memory has finally reached its end — and the chain at the center of it is one Americans trust with their most personal healthcare needs. Walgreens has agreed to pay more than $100 million to resolve claims that it systematically overcharged insured patients for generic prescription drugs, a practice the lawsuit traced back nearly two decades. The settlement closes a chapter on litigation that has wound through federal court since 2017 and implicates millions of Americans who filled prescriptions using private insurance, Medicare, or Medicaid.
The Case: Russo et al. v. Walgreen Co.
The lawsuit, filed March 23, 2017 in the U.S. District Court for the Northern District of Illinois as Russo et al. v. Walgreen Co., No. 1:17-cv-02246, rests on a straightforward but damaging allegation: Walgreens kept two sets of prices — one for cash-paying customers enrolled in its Prescription Savings Club, and a higher one reported to insurers as its "usual and customary" rates.
Lead plaintiff Cynthia Russo, a Florida resident who carried Medicare and Medicare Part D coverage, purchased generic versions of more than ten medications from Walgreens between January 1, 2012 and the filing date. Her assumption — a reasonable one shared by most insured Americans — was that her insurance coverage would ensure she paid no more than a cash-paying customer at the same pharmacy counter. According to the complaint, that assumption was wrong, and she would not have paid the inflated prices had she known what Walgreens was doing.
What Walgreens Was Accused of Doing
At the heart of this case is Walgreens' Prescription Savings Club, a membership program that offered cash-paying customers access to more than 500 commonly prescribed generics for $5, $10, and $15 for 30-day supplies, and $10, $20, and $30 for 90-day supplies — all for a nominal annual fee. The program was available only to customers paying out of pocket, without using insurance.
The problem, plaintiffs argued, was that Walgreens never factored those deeply discounted club prices into the "usual and customary" prices it reported to insurers and third-party payers. Under standard industry practice, "usual and customary" pricing is supposed to reflect what a pharmacy actually charges its cash customers. By excluding Prescription Savings Club prices from that calculation, Walgreens allegedly caused insurers and other third parties to reimburse at inflated rates — and insured patients to pay more out of pocket than they should have. The lawsuit sought damages for insured customers nationwide dating back to 2007, the year the Prescription Savings Club launched.
Walgreens denied the allegations outright. The company maintained that reporting its retail prices as usual and customary was entirely appropriate. In a statement following the settlement, a Walgreens spokesperson said, "We admit no liability and believe these claims never had any merit. This resolution allows us to focus on our turnaround strategy that will benefit our patients, customers, team members and shareholders." Plaintiffs' attorneys, for their part, called the outcome an "excellent result" for the class.
The $100 Million Resolution
Walgreens agreed to deposit $100,000,000 into a Settlement Fund to resolve all claims brought on behalf of class members — individuals, third-party payors, health insurers, and other entities that paid for prescription drugs at Walgreens during the relevant period. The money will be distributed according to a Plan of Allocation and Distribution approved by the court.
Beyond the financial payout, Walgreens also agreed to terminate the Prescription Savings Club program entirely. The club was shut down in August, a structural concession that signals something more than a check written to make litigation go away.
Under the distribution plan, individual consumers will receive a proportional share of 20 percent of the net settlement fund, calculated based on their prescription purchases. Third-party payors — the insurers and other entities that reimbursed Walgreens on behalf of patients — will split the remaining 80 percent on the same proportional basis. Class counsel, the prominent plaintiffs' firm Robbins Geller Rudman & Dowd LLP, will ask the court for attorneys' fees not exceeding 30 percent of the fund, out-of-pocket costs and expenses capped at $3,000,000, service awards up to $5,000 for each individual plaintiff and $15,000 for each fund plaintiff, and notice and administration expenses. Exact individual payouts depend on how many valid claims were submitted and the amount each claimant paid for prescriptions at Walgreens.
Who the Settlement Covers
The settlement class includes individuals and entities that, between January 1, 2007 and November 18, 2024, paid — in whole or in part — for one or more prescription drugs from Walgreens when insurance benefits were used to fill the prescription.
Several groups are excluded. Walgreens employees, management, and affiliates do not qualify. Neither do pharmacy benefit managers, individuals who paid for all their Walgreens prescriptions entirely without insurance during the class period, or federal and state government entities — with the exception of government-funded employee benefit plans.
The settlement was preliminarily approved on November 18, 2024. Claims deadlines have since passed: consumers who requested their prescription purchase data from Walgreens on or before April 12, 2025 had until June 16, 2025 to submit a claim. All other class members faced an April 17, 2025 deadline. The court-approved settlement website, SavingsClubSettlement.com, remains a resource for information, administered by A.B. Data, Ltd. Class counsel includes attorneys David Mitchell and Arthur L. Shingler III at Robbins Geller's San Diego office at 655 West Broadway, Suite 1900.
Not an Isolated Case
This settlement doesn't exist in a vacuum. In a separate matter, Walgreens agreed to pay $106.8 million to resolve allegations that it billed federal healthcare programs — Medicare, Medicaid, and others — for prescription drugs that were processed but never actually picked up by patients. That conduct was alleged to have taken place between 2009 and 2020.
The two cases together paint a picture of a company that, at various points, faced serious questions about billing integrity. For consumer advocates who have long argued that pharmacy pricing lacks transparency, the scrutiny is neither surprising nor, they would argue, sufficient.
Why This Case Matters Beyond Walgreens
The "usual and customary" pricing framework isn't a Walgreens-specific concept — it's the mechanism by which insurers and pharmacy benefit managers calculate reimbursements across the entire prescription drug industry. When a major pharmacy chain is found to have potentially manipulated those figures by operating a parallel discount program invisible to insurers, the implications don't stop at one company's balance sheet. They invite a broader question: is this happening elsewhere?
Russo et al. v. Walgreen Co. spans nearly 18 years of alleged overcharges and touches virtually every insured American who filled a prescription at Walgreens during that stretch. As a precedent, it reinforces that "usual and customary" pricing is not merely an administrative formality — it's a consumer protection issue, and the courts are willing to treat it as one.
This article is for informational purposes only and does not constitute legal advice. If you believe you have been affected by similar pharmaceutical pricing practices, consult a qualified attorney to understand your options.